Massive intraventricular hemorrhage (IVH) in neonates is followed by progressive ventricular dilatation in 55-80% of cases if the infant survives. The initial mechanism of post hemorrhagic hydrocephalus (PHH) is thought to be obstruction by multiple small blood clots of the channels of the cerebrospinal fluid (CSF) to areas of absorption. Plasminogen activator inhibitor-1 (PAI-1) is the principal regulator of fibrinolysis in blood and one of the most highly controlled of the fibrinolytic components. The aim of this study is to measure plasminogen and plasminogen activator inhibitor-1 levels in the CSF of the neonates after IVH to assess endogenous fibrinolytic activity and to predict the development of post hemorrhagic hydrocephalus. Fifteen full term and preterm neonates with IVH were enrolled in the study. Ten neonates without IVH were used as a control group. Cranial ultrasound was performed at age of 2 weeks and 2 months. Plasma and CSF plasminogen and PAI-1 levels were assessed for these neonates. The results revealed that CSF PAI-1 was significantly higher in infants with IVH than in the controls (P<0.001). There was no significant difference in the CSF and plasma plasminogen between infants with IVH and controls (p>0.05). CSF PAI-1 was significantly higher in infants with PHH than in infants with post hemorrhagic ventricular dilatation (p<0.05), with a sensitivity (100%) and specificity (100%). Conclusion: CSF PAI-1 is a very sensitive and specific parameter than CSF plasminogen for prediction of PHH in neonates with IVH, and this might be useful to evaluate the specific therapeutic programs of these neonates.
Introduction:
Massive intraventricular hemorrhage (IVH) in neonates is followed by progressive ventricular dilatation in 55-80% of cases if the infant survives. 1 Post hemorrhagic hydrocephalus (PHH) is a serious complication of cerebral intraventricular hemorrhage, especially in premature infants. 2 The initial mechanism of PHH is thought to be obstruction by multiple small blood clots of the channels of the cerebrospinal fluid (CSF) to areas of absorption. Thus, we can expect to find evidence in the CSF of activation of plasminogen to the active enzyme plasmin, which then split fibrin into fibrin degradation products. 3 Tissue plasminogen activator (TPA) can be demonstrated in the CSF after IVH but fibrinolytic activity is often not demonstrable for several weeks of IVH. Fibrinolysis can be enhanced by exogenous plasminogen activation in the CSF, thus helping to clear blood clots and avoid PHH. 3 Intraventricular urokinase reduced the severity of PHH in animal model and intracisternal (TPA) reduced the severity of PHH in a cat model. 4 Experience with intraventricular fibrinolytic therapy using streptokinase or urokinase or TPA in premature infants showed that half the infants fail to respond to therapy in that they eventually require a ventriculoperitoneal shunt. The presence of an inhibitor of fibrinolysis could explain some of the therapeutic failure. 5 Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of the endogenous plasminogen activator, namely TPA and urokinase-type plasminogen activator. 6 PAI-1 is the principal regulator of fibrinolysis in blood and one of the most highly controlled of the fibrinolytic components, a change in its activity whether natural or experimental can disrupt the normal fibrinolytic activity. High PAI-1 level can also inhibit exogenous fibrinolytic therapy. 7 The aim of this study is to measure plasminogen and plasminogen activator inhibitor-1 (PAI-1) levels in the CSF of neonates after IVH to assess endogenous fibrinolytic activity and to predict the development of post hemorrhagic hydrocephalus (PHH).
Subjects and Methods:
The present study was conducted in the Neonatal Unit, Pediatric Department, Tanta University Hospital. Fifteen full term and preterm neonates; with gestational age between 28 and 42 weeks were enrolled in this study. The neonates were presented by intraventricular hemorrhage and signs of blood loss as shock, pallor, respiratory distress, jaundice and disseminated intravascular coagulation. Also, signs of neurological dysfunction as bulging anterior fontanel, excessive somnolence, hypotonia, weakness, seizures, temperature instability, brain stem signs as apnea, lost extra ocular movement and facial weakness (table I) . Laboratory correlates of blood loss were done as metabolic acidosis, hypercarbia and respiratory acidosis, thrombocytopenia, prolonged PT, PTT and hyperbilirubinemia. Seven infants of these neonates had developed ventricular dilatation and eight infants had developed post hemorrhagic hydrocephalus (PHH) demonstrated by (cranial ultrasound). Ten control neonates with gestational age ranged from 28 to 42 weeks without IVH were enrolled in the study. Lumbar puncture was carried out to exclude meningitis in the setting of a clinical suspicion of infection. All these neonates were subjected to the following: 1. Cranial ultrasonography at two weeks and after two months age. 2. Plasma plasminogen and plasminogen activator inhibitor-1(PAI-1) assay. 3. CSF plasminogen and plasminogen activator inhibitor-1(PAI-1) assay. Cranial Ultrasonography: Cranial ultrasound was performed for every infant, using (Acoustic Imaging (AI-5200S), Envision, Dornier Company, with a 5MHz transducer). Post-hemorrhagic ventricular dilatation was considered at ventricular width 4mm over the 97 th percentile for gestational age, whereas post hemorrhagic hydrocephalus was diagnosed by progressive ventricular and head circumference enlargement.8
Plasminogen:
It was measured using immunodiffusion technique (M Partigen Plasminogen. Behringwerke AG. Marburg.
Germany). 9 The immunodiffusion plates contain monospecific antiserum to plasminogen in an agar gel layer with 12 wells cut into each plate. A standard curve was derived by adding to three of the wells on each 25μl of standard adult human plasma diluted 1 in 10, 1 in 20 or 1 in 40. The remaining wells on each plate were used for CSF samples. Because of the low concentration of plasminogen in CSF, each sample of CSF was concentrated by a factor of 6-50 times using water extraction via a collodion membrane; 25μl of concentrated CSF was used in each well. Plasminogen activator inhibitor-1: It was measured by enzyme-linked immunosorbant assay (ELISA) using the (Bipool tintElize PAI-1 Kit) 10 for quantitative determination of PAI-1 in the plasma and body fluids by ELISA method. This assay measures total PAI-1 concentrations including free and inactive forms. CSF standard have not determined for this assay, but normal plasma values ranges from 4-43 ng/ml. The lowest limit detectable with this assay is 6 ng/ml.
Statistical Analysis:
Data were expressed as mean ± SD. The student's "t" test was used to compare between two groups of patients. Sensitivity and specificity were calculated for estimation of predictive ability. Data were considered statistically significant at p<0.05. 11 qwle II shows the CSF plasminogen activator inhibitor-1 in infants with and without IVH. Infants without IVH had no detectable PAI-1 while all infants with IVH had detectable PAI-1 in the CSF with the range between 6-230 ng/ml, and the mean value 76±77.4 ng/ml. The difference between these two groups was highly significant (p<0.001). Table III shows the CSF plasminogen of infants without IVH with the range 0.45-1.1% and the mean value was 0.57±0.52%. The range of CSF plasminogen in infants with IVH was 0-1.2% with the mean value was 0.74±0.25%. The difference between these two groups was not significant (p>0.05). Table IV shows the plasma PAI-1 in infants without IVH with the range 6-43 ng/ml, and the mean value was 22±8.4ng/ml. The range of plasma PAI-1 in infants with IVH was 6-55ng/ml with the mean value 31±6.2 ng/ml. The difference between these two groups was not significant (p>0.05). Table IV also shows the plasma plasminogen values in infants with and without IVH. In infants without IVH, the range of plasma plasminogen was 1-2.3U/ml, and the mean value was 1.64±0.45 U/ml. The range of plasma plasminogen in infants with IVH was 1.05-2.4 U/ml and the mean value was 1.66±0.47 U/ml. The difference between these two groups was not significant (p>0.05). Table V shows a comparison between the ventricular size in infants with and without IVH (by cranial ultrasonography). At age of two weeks, in infants without IVH, the range was (4-7mm) with the mean value was 5.2±0.82 mm. In infants with IVH, the range of ventricular size was 7-12 mm with the mean value was 8.7±1.5 mm. The difference between both groups was statistically significant (p<0.05). After two months, the range of the ventricular width in infants with IVH was 8-15 mm with the mean value was 12.5±2.4 mm. The difference between both groups was highly significant (p<0.001). Table VI shows the CSF PAI-1 in infants with PHH with the range was 44-230 ng/ml and the mean value was 125.37±76.9 ng/ml. In infants with post hemorrhagic ventricular dilatation, the range of CSF PAI-1 was 6-35 ng/ml and the mean value was 19.6±10.27 ng/ml. The difference between both groups was statistically significant (p<0.05). Table VI also shows the CSF plasminogen in infants with PHH with the range 0-0.8% and the mean value was 0.14±0.27%. In infants with post hemorrhagic ventricular dilatation, the CSF plasminogen range was 0.9-1.2% with the mean value 1.07±0.11%. The difference between both groups was statistically significant (p<0.05). Table VII shows the sensitivity and specificity of CSF PAI-1 and CSF plasminogen in neonates with IVH as predictors of PHH. It shows that the sensitivity of both parameters was 100% and 46.7% respectively, while the specificity was 100% and 50% respectively.
Results :

Discussion:
Our results showed that CSF of control neonates had no detectable PAI-1 but PAI-1 was detectable in the CSF of all infants with IVH (sensitivity 100% and specificity 100%). Infants with IVH who had developed PHH (demonstrated by cranial ultrasonography) had the highest level of PAI-1 in the CSF; they also had the lowest level of CSF plasminogen than infants with IVH who had developed post hemorrhagic ventricular dilatation. This finding has several explanations. Kishnamurti and Alving, 12 in their study, reported that the original hemorrhage could have introduced PAI-1 into the CSF, platelets are known to contain high levels of PAI-1, also the plasma itself contains PAI-1, so the whole blood of the original hemorrhage may have triggered synthesis or release of PAI-1 in the CNS. Moreover, another study carried out by Sutton et al.. 13 reported that the brain also responds to certain pathological conditions with an increased rate of transudation of PAI-1 from the plasma into CSF, secretion from choroid plexus, or local intracerebral synthesis, as in CNS hemorrhage, cerebral infarction, CNS infections and IVH or tumors. Rao et al., 14 in another study, said that plasma PAI-1 in normal and stressed infants revealed mean values of 35±17 ng/ml and 66±15ng/ml, respectively, with significant difference, which did not agree with our results as regards plasma PAI-1 (table IV) . Luskutoff 15 had reported that elevated plasma PAI-1 levels are associated with thrombosis in animals and adult humans and elevated CSF PAI-1 levels may be markers for CNS diseases. CSF PAI-1 levels were 15 folds higher in adults with hemorrhage into the CSF than in controls, although they were not increased in adults with congenital hydrocephalus. These results were in agreement with our results. PAI-1 may play an important role in regulating the function of tissue plasminogen activator (TPA) in the CSF. In normal human plasma, PAI-1 is the primary inhibitor of the endogenous plasminogen activators. High PAI-1 level can also inhibit exogenous fibrinolytic therapy. 1 Hansen et al., 16 in their study, had found that high PAI-1 is associated with failure of treatment of PHH with fibrinolytic therapy early in the neonatal period. Andrew et al. 17 have shown that clot lysis in infants with IVH failed to respond to exogenous streptokinase; this finding may be due to PAI-1 inhibition of exogenous plasminogen activators, also newborn infants have physiologic hypofibrinolytic state as determined by an analysis of the components of the lytic system. The normal newborn has hypofibrinogenemia, low TPA activity and increased PAI-1 antigen as compared with adults. Whitelaw et al. 18 had reported that infants with high CSF PAI-1 failed to respond to streptokinase treatment, and PAI-1 may be a marker for the disease severity. Whitelaw et al., 19 in their study, had found that the CSF plasminogen in neonates with IVH is about less than 1% of the plasma plasminogen level, which was in agreement with our results. This low plasminogen suggested that the source of plasminogen in the CSF was diffusion across a damaged blood brain barrier. Also, plasminogen could have been derived from blood in the original hemorrhage or it would likely to be bound to fibrin in the thrombi. Another possible explanation for the low CSF levels of plasminogen after IVH is that the tissue plasminogen activators present had already activated all the available plasminogen into plasmin. Whitelaw et al. 19 concluded that endogenous fibrinolysis and the potential for fibrinolytic treatment in the CSF may be limited by low concentration of plasminogen and administration of recombinant plasminogen may assist attempts to clear intraventricular blood clots. Moreover, Nowak et al. 7 reported that some infants with IVH do not show rapid clot lysis and have permanent hydrocephalus despite large doses of intraventricular streptokinase or high concentration of TPA. Lack of efficacy of fibrinolytic therapy may be due to accumulation of red blood cells or an inflammatory cellular reaction not amenable to fibrinolysis. Another possible explanation for treatment failure in infants with PHH may de due to limited availability of plasminogen at the thrombus site. 20 Andrew et al. 21 said that CSF plasminogen concentration of less than 1% of normal plasma value may be insufficient to produce an optimal fibrinolytic response when activated by tissue plasminogen activator, so these infants develop PHH as a result of obstruction of the channels of the CSF by multiple small blood clots. This deficiency of plasminogen together with elevated level of PAI-1 combine to increase the chance for thrombus formation and the development of PHH after IVH in neonates.
Conclusions:
1. Neonates with IVH have limited endogenous fibrinolytic activity, with the development of PHH in many cases. 2. CSF PAI-1 and plasminogen can be used as predictors of PHH in neonates with IVH. PAI-1 is a very sensitive and specific predictor than plasminogen as a diagnostic and prognostic parameter. 3. These data might be useful to evaluate the specific therapeutic programs of neonates with IVH and PHH, either medical or surgical .
